<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03880045</url>
  </required_header>
  <id_info>
    <org_study_id>aswu/206/19</org_study_id>
    <nct_id>NCT03880045</nct_id>
  </id_info>
  <brief_title>Topical Tranexamic Acid Plus Perivascular Vasopressin at the Time of Abdominal Myomectomy</brief_title>
  <official_title>Topical Tranexamic Acid Plus Perivascular Vasopressin to Decrease Bleeding at the Time of Abdominal Myomectomy: A Double-blinded Randomized Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aswan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aswan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators will investigate the effectiveness of a topical tranexamic
      acid plus perivascular vasopressin compared with perivascular vasopressin alone for the
      reduction of blood loss at the time of myomectomy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Uterine fibroids are the most common female pelvic tumors occurring in about 15% to 30% of
      women in the reproductive age group. The major problem with myomectomy is excessive bleeding
      from the increased uterine blood supply. This can be life-threatening, resulting in blood
      transfusions, febrile morbidity, and potentially in loss of reproductive potential from a
      hysterectomy. Knowledge of the effectiveness of the interventions used to reduce blood loss
      during myomectomy is essential to enable evidence-based clinical decisions. Topical
      application of tranexamic acid(TA) provides a high drug concentration at the site of the
      wound and a low systemic concentration. Studies from cardiac and orthopedic surgery have
      shown an equal or superior effect of topical compared with intravenous TA on both bleeding
      and transfusion requirement. Topical treatment is cost-effective, and adverse effects or drug
      interactions have not been reported
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A double-blinded randomized controlled stud</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>A double-blinded randomized controlled stud</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>measure will be Mean amount of blood loss</measure>
    <time_frame>intraoperative</time_frame>
    <description>measure will be Mean amount of blood loss by gravimetric methods</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the number of the patients need of blood transfusion</measure>
    <time_frame>24 hours post delivery</time_frame>
    <description>calculate the number of the patients need of blood transfusion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Myoma</condition>
  <arm_group>
    <arm_group_label>Topical TA plus vasopressin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intraoperative perivascular injection of one ampoule of vasopressin containing 20 units in 1 ml after dilution in 19 ml of normal saline during myomectomy plus gauze soaked with 2 g tranexamic acid (20 ml) diluted in 100 ml of sodium chloride0.9%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo to TA plus vasopressin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intraoperative perivascular injection of one ampoule of vasopressin containing 20 units in 1 ml after dilution in 19 ml of normal saline during myomectomy plus placebo to tranexamic acid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical TA</intervention_name>
    <description>A gauze soaked with 2 g tranexamic acid (20 ml) diluted in 100 ml of sodium chloride0.9%</description>
    <arm_group_label>Topical TA plus vasopressin</arm_group_label>
    <other_name>Active comparator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vasopressin</intervention_name>
    <description>intraoperative perivascular injection of one ampoule of vasopressin containing 20 units in 1 ml after dilution in 19 ml of normal saline during myomectomy</description>
    <arm_group_label>Topical TA plus vasopressin</arm_group_label>
    <arm_group_label>placebo to TA plus vasopressin</arm_group_label>
    <other_name>Active Comparator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo to TA</intervention_name>
    <description>(120 ml of sodium chloride 0.9%) used to compress the myoma bed for 5 min.</description>
    <arm_group_label>placebo to TA plus vasopressin</arm_group_label>
    <other_name>placebo comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients presenting for abdominal myomectomy with documented uterine fibroids on
             pelvic imaging

          -  Age ≥ 18 years and ≤ 50 years

          -  Pre-operative hemoglobin &gt;8 g/dl

          -  Ability to understand and the willingness to sign a written informed consent.

          -  Admissible medical/surgical history

          -  Five or less symptomatic uterine myomas

          -  All myomas are subserous or intramural.

          -  Uterine size less than 24 weeks of pregnancy

        Exclusion Criteria:

          -  Patients who have had a prior abdominal myomectomy

          -  Post-menopausal women

          -  Patients with known bleeding/clotting disorders

          -  Patients with a history of gynecologic malignancy

          -  Hypertension.

          -  Cardiac and Pulmonary Diseases.

          -  Obesity (body mass index &gt; 30 kg/m2).

          -  History of allergic reactions attributed to misoprostol

          -  Cases that will require intraoperative conversion of myomectomy to hysterectomy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>All women who prepared for abdominal myomectomies will be invited to participate in the study</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>hany f allam, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aswan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>hany f allam, md</last_name>
    <phone>0102236052</phone>
    <phone_ext>002</phone_ext>
    <email>hany.farouk@aswu.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>nahla w shady, md</last_name>
    <phone>01092440504</phone>
    <phone_ext>002</phone_ext>
    <email>nahla.elsayed@aswu.edu.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aswan University Hospital</name>
      <address>
        <city>Aswan</city>
        <zip>81528</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hany F Sallam, MD</last_name>
      <phone>0122336052</phone>
      <phone_ext>002</phone_ext>
      <email>hany.farouk@aswu.edu.eg</email>
    </contact>
    <contact_backup>
      <last_name>Nahla W Shady, MD</last_name>
      <phone>01092440504</phone>
      <phone_ext>002</phone_ext>
      <email>nahla.elsayed@aswu.edu.eg</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>March 15, 2019</study_first_submitted>
  <study_first_submitted_qc>March 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <last_update_submitted>May 10, 2019</last_update_submitted>
  <last_update_submitted_qc>May 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aswan University Hospital</investigator_affiliation>
    <investigator_full_name>hany farouk</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>abdominal myomectomy</keyword>
  <keyword>tranexamic acid</keyword>
  <keyword>vasopressin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasopressins</mesh_term>
    <mesh_term>Arginine Vasopressin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

